MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Retained Earnings 2011-2026 | SNOA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -198 M | -194 M | -190 M | -184 M | -179 M | -172 M | -169 M | -157 M | -143 M | -152 M | -142 M | -134 M | -138 M | -132 M | -125 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -125 M | -198 M | -161 M |
Quarterly Retained Earnings Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -200 M | -200 M | -199 M | -198 M | -197 M | -196 M | -195 M | -194 M | -193 M | -192 M | -191 M | -190 M | -188 M | -186 M | -185 M | -184 M | -181 M | -180 M | -180 M | -179 M | -173 M | -172 M | -172 M | -171 M | -171 M | -170 M | -169 M | -169 M | -166 M | -164 M | -161 M | -157 M | -153 M | -149 M | -147 M | -143 M | -141 M | -157 M | -155 M | -152 M | -149 M | -146 M | -145 M | -142 M | -141 M | -135 M | -134 M | -134 M | -141 M | -141 M | -139 M | -138 M | -135 M | -133 M | -132 M | -132 M | -131 M | -128 M | -127 M | -125 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -125 M | -200 M | -163 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-472 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
-703 M | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
-157 M | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-353 M | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
-183 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-661 M | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-698 M | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-385 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-958 M | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
-295 M | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
-300 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-403 M | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-47.2 M | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-952 M | $ 2.07 | 0.98 % | $ 23.9 M | USA |